Video Player
00:00
00:00
- Physical Examination
- Surgical Examination
- Ophthalmology
- Clinical Skills
- Orthopedics
- Surgery Videos
- Laparoscopy
- Pediatrics
- Funny Videos
- Cardiothoracic Surgery
- Nursing Videos
- Plastic Surgery
- Otorhinolaryngology
- Histology and Histopathology
- Neurosurgery
- Dermatology
- Pediatric Surgery
- Urology
- Dentistry
- Oncology and Cancers
- Anatomy Videos
- Health and Fitness
- Radiology
- Anaesthesia
- Physical Therapy
- Pharmacology
- Interventional Radiology
- Cardiology
- Endocrinology
- Gynecology
- Emergency Medicine
- Psychiatry and Psychology
- Childbirth Videos
- General Medical Videos
- Nephrology
- Physiology
- Diet and Food Health
- Diabetes Mellitus
- Neurology
- Women Health
- Osteoporosis
- Gastroenterology
- Pulmonology
- Hematology
- Rheumatology
- Toxicology
- Nuclear Medicine
- Infectious Diseases
- Vascular Disease
- Reproductive Health
- Burns and Wound Healing
- Other
Brain Cancer Vaccine
0
0
10,566 Views·
01/17/24
Source ABC7, 24 November 2009 An initial single-arm Phase II trial (ACT II) has reported promising preliminary data in 23 patients who received CDX-110 vaccine. Median time to disease progression was 16.6 months and estimated median overall survival was 33.1 months. This compared favorably with data for a historical control group in which median time to progression was 6.4 months and median overall survival was 15.2 months. The study was sponsored by Celldex Therapeutics Inc. of Phillipsburg, NJ
Show more
0 Comments
sort Sort By